Albuminuria, expression of nicotinamide adenine dinucleotide phosphate oxidase and monocyte chemoattractant protein-1 in the renal tubules of hypertensive Dahl salt-sensitive rats

Hypertension Research

Volumn 30, Issue 10, 2007, Pages 991-998

  Fujii, Shigemoto ^a   Zhang, Ling ^a   Kosaka, Hiroaki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Albuminuria; Dahl rats; Hydralazine; Monocyte chemoattractant protein 1; Nicotinamide adenine dinucleotide phosphate oxidase

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; GLYCOPROTEIN; GLYCOPROTEIN GP 47 PHOX; HYDRALAZINE; HYDROGEN PEROXIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HIGH SODIUM INTAKE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY TUBULE; KIDNEY TUBULE ABSORPTION; MALE; MONONUCLEAR CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RAT; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; CHEMOKINE CCL2; GENE EXPRESSION; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULES; MALE; NADPH OXIDASE; RATS; RATS, INBRED DAHL;

EID: 36248936493     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.991     Document Type: Article

References (44)

1. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15.
2. Kohara K, Tabara Y, Tachibana R, Nakura J, Miki T: Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) study. Hypertens Res 2004; 27: 471-477.
3. Tanaka M, Babazono T, Takeda M, Iwamoto Y: Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens Res 2006; 29: 345-352.
4. Munakata M, Nunokawa T, Yoshinaga K, Toyota T: Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension - a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res 2006; 29: 515-521.
5. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997; 8: 1537-1545.
6. 2 through a PKC-dependent pathway. J Am Soc Nephrol 2002; 13: 1179-1189.
7. Eddy AA: Proteinuria and interstitial injury. Nephrol Dial Transplant 2004; 19: 277-281.
8. Tolins JP, Raij L: Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990; 16: 452-461.
9. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T: Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure. Hypertension 2002; 40: 834-839.
10. Fujii S, Zhang L, Igarashi J, Kosaka H: L-Arginine reverses p47phox and gp91phox expression induced by high salt in Dahl rats. Hypertension 2003; 42: 1014-1020.
11. Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlondorff D: Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest 1993; 92: 1564-1571.
12. Tanifuji C, Suzuki Y, Geot WM, et al: Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid Redox Signal 2005; 7: 1261-1268.
13. Lakshminarayanan V, Lewallen M, Frangogiannis NG, et al: Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001; 159: 1301-1311.
14. Wung BS, Cheng JJ, Hsieh HJ, Shyy YJ, Wang DL: Cyclic strain-induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein 1. Circ Res 1997; 81: 1-7.
15. Taal MW, Chertow GM, Rennke HG, et al: Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol Renal Physiol 2001; 280: F343-F355.
16. Gong R, Rifai A, Tolbert EM, Biswas P, Centracchio JN, Dworkin LD: Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol 2004; 15: 2868-2881.
17. Pichler RH, Franceschini N, Young BA, et al: Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186-1196.
18. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984; 26: 137-143.
19. Danoff TM: Chemokines in interstitial injury. Kidney Int 1998; 53: 1807-1808.
20. Cathcart MK: Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 23-28.
21. Rollins BJ, Walz A, Baggiolini M: Recombinant human MCP-1/JE induces chemotaxis, calcium flux, and the respiratory burst in human monocytes. Blood 1991; 78: 1112-1116.
22. Zachariae CO, Anderson AO, Thompson HL, et al: Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J Exp Med 1990; 171: 2177-2182.
23. Schecter AD, Rollins BJ, Zhang YJ, et al: Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997; 272: 28568-28573.
24. Jiang Y, Beller DI, Frendl G, Graves DT: Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992; 148: 2423-2428.
25. Gharaee-Kermani M, Denholin EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271: 17779-17784.
26. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T: Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000; 164: 6174-6179.
27. Yao K, Sato H, Ina Y, Suzuki K, Ohno T, Shirakura S: Renoprotective effects of benidipine in combination with angiotensin II type 1 receptor blocker in hypertensive Dahl rats. Hypertens Res 2003; 26: 635-641.
28. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T: Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006; 47: 1084-1093.
29. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
30. Dworkin LD, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 1996; 27: 245-250.
31. Karam H, Clozel JP, Bruneval P, Gonzalez MF, Menard J: Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. Hypertension 1999; 34: 673-678.
32. Iino Y, Hayashi M, Kawamura T, et al: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension - a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21-30.
33. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM: Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1994; 23: 195-199.
34. Imanishi M, Yoshioka K, Konishi Y, et al: Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999; 42: 999-1005.
35. Koya D, Lee IK, Ishii H, Kanoh H, King GL: Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 1997; 8: 426-435.
36. Sochman J: N-Acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?! J Am Coll Cardiol 2002; 39: 1422-1428.
37. Ho E, Chen G, Bray TM: Supplementation of N-acetylcysteine inhibits NFkappaB activation and protects against alloxan-induced diabetes in CD-1 mice. FASEB J 1999; 13: 1845-1854.
38. Qanungo S, Wang M, Nientinen AL: N-Acetyl-L-cysteine enhances apoptosis through inhibition of nuclear factor-kappaB in hypoxic murine embryonic fibroblasts. J Biol Chem 2004; 279: 50455-50464.
39. Sury MD, Frese-Schaper M, Muhlemann MK, et al: Evidence that N-acetylcysteine inhibits TNF-alpha-induced cerebrovascular endothelin-1 upregulation via inhibition of mitogen- and stress-activated protein kinase. Free Radic Biol Med 2006; 41: 1372-1383.
40. Hao CM, Yull F, Blackwell T, Komhoff M, Davis LS, Breyer MD: Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest 2000; 106: 973-982.
41. Zhou X, Ferraris JD, Cai Q, Agarwal A, Burg MB: Increased reactive oxygen species contribute to high NaCl-induced activation of the osmoregulatory transcription factor TonEBP/OREBP. Am J Physiol Renal Physiol 2005; 289: F377-F385.
42. Holt S, Goodier D, Marley R, et al: Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999; 353: 294-295.
43. Olney JW, Zorumski C, Price MT, Labruyere J: L-Cysteine, a bicarbonate-sensitive endogenous excitotoxin. Science 1990; 248: 596-599.
44. Shimizu MH, Coimbra TM, de Araujo M, Menezes LF, Seguro AC: N-Acetylcysteine attenuates the progression of chronic renal failure. Kidney Int 2005; 68: 2208-2217.